ISM RESEARCH GROUP Trademark

A pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals, namely, for treatment of AIDS, infectious diseases; a pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on humans, namely, for AIDS, infectious diseases, a pharmaceutical composition featuring a pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 %, wherein the selected isotopes include stable isotopes having at least one of K-39, Mg -24, Zn-64, Rb-85, Si-26 and combination thereof and all other isotopes, wherein the pharmaceutical carrier is in the form of a solution, a gel, a cream, a spray, an aerosol, a patch, nanoparticles, inorganic molecules, organic molecules, a plant, a fruit and a vegetable, the pharmaceutical composition for treating AIDS, infectious diseases

medical services featuring a pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals featuring a pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of stable isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 % and administering a first of the stable isotopes at least prior to and after surgical removal of a solid tumor to prevent possible metastases and occurrence of secondary effects and to prevent metastasizing followed by administering a second of the stable isotopes to transform a cancer cell phenotype into a normal cell, wherein the pharmaceutical carrier and an isotope selective ingredient having at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100 %, wherein the selected isotopes include stable isotopes having at least one of K-39, Mg -24, Zn-64, Rb-85, Si-26 and combination thereof and all other isotopes, wherein the pharmaceutical carrier is in the form of a solution, a gel, a cream, a spray, an aerosol, a patch, nanoparticles, inorganic molecules, organic molecules, a plant, a fruit and a vegetable; medical testing for diagnostics purposes for diagnosis of pathology in biological objects featuring comparative analysis of light and heavy isotopes concentrations of vital chemical elements, wherein concentrations of light and heavy isotopes are compared to the ones corresponding to a natural distribution of isotopes for a given chemical element